We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

    • Streptococcus pneumoniae

    Health

    CDC Recommends Pneumococcal Vaccination for Adults Aged 50 and Older

    The CDC’s Advisory Committee on Immunization Practices has recommended pneumococcal vaccinations for adults aged 50 and older, expanding previous guidelines focused on those 65 and older. This pivotal change aims to protect more individuals from serious infections like pneumonia and meningitis, amidst evolving competition in the vaccine market.

    Posted on Jhon
    Health

    Mapping Pathogen Spread Through Human Travel Patterns

    Learn how researchers are tracking the spread and evolution of superbugs by combining genomic data with human travel patterns. Insights from the study could help predict and prevent future outbreaks, especially for pathogens like Streptococcus pneumoniae. Discover how initial reductions in antibiotic resistance linked to vaccines may be temporary, and how non-targeted strains resistant to antibiotics gain a competitive advantage.

    Posted on Jhon
    Health

    Merck’s V116 Pneumococcal Conjugate Vaccine Shows Positive Data in Phase 3 Studies

    Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, has shown positive data from multiple Phase 3 studies, offering potential clinical value to a range of adult populations. The vaccine has been found to be immunogenic for all 21 serotypes covered by the vaccine in various adult populations, including those at an increased risk of pneumococcal disease. If approved, V116 would be the first pneumococcal conjugate vaccine designed specifically for adults, providing confidence in its potential clinical value.

    Posted on Jhon